DHX9 and obesity due to melanocortin 4 receptor deficiency: Conclusions: These results indicate that Rha inhibits invasive behavior and VM in TNBC cells by interfering with the leptin–STAT3–AQP1 signaling pathway, suggesting that Rha is a promising therapeutic candidate for the treatment of obesity-associated TNBC.